The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

GSK is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 8.48; value investors should ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

April 15 (Reuters) - British pharmaceutical giant GSK (GSK.L), opens new tab has not ... his job cuts hobble black lung protections for miners 3:23 PM UTC · Updated ago Future of Healthcategory ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...